Agendia Genomic Test for Molecular Subtyping of Breast Cancer Is a Better Guide to Pre-Surgical Treatment Study Finds

Agendia Genomic Test for Molecular Subtyping of Breast Cancer Is a Better Guide to Pre-Surgical Treatment Study Finds
Genomic TestA new study entitled “Chemosensitivity Predicted by BluePrint 80-Gene Functional Subtype and MammaPrint in the Prospective Neoadjuvant Breast Registry Symphony Trial (NBRST)“ and published in the Annals of Surgical Oncology, has found that Agendia's BluePrint genomic test provides more accurate information about the molecular subtype of a specific breast cancer, compared to the use of conventional Immunohistochemistry-FISH pathology tests. Furthermore, according to the observational study of 426 patients, the 80-gene BluePrint test reclassified 22% of tumors overall, more accurately identifying breast cancer subtypes than could be done with IHC-FISH testing. The BluePrint test is performed together with another Agendia´s test, the 70-gene MammaPrint. While the latter classifies cancer risk in High Risk or Low Risk, for breast cancer recurrence, 80-gene BluePrint assay identifies the tumor molecular type. Pat Whitworth M.D., a Nashville surgical oncologist and leading author of this study noted in a company's press release,, “This genomic test gives us a better picture of which patients will
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.